The rise of copyright’s blockbuster initially drove a boom for the drug industry, but recent changes present a complicated scenario for shareholders. Lower-cost alternatives are eroding revenue, and ongoing patent https://lilyrtng966556.59bloggers.com/41528270/sildenafil-and-big-pharma-a-risky-play